REGN-COV2

Category

U.S. FDA Authorizes Regeneron’s REGN-COV2 Monoclonal Antibody for Emergency Use Authorization Targeting Select COVID-19 Patients

The monoclonal antibody cocktail developed by Regeneron and made well-known by POTUS during his stay at Walter Reed Medical Center has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Initially called REGN-COV-2 and also...

Atrium Health Helps Pave Path Toward Clinical Research as a Care Option Targeting COVID-19 with Three New Clinical Trials Offering Outpatient Hope

Atrium Health, formerly the Carolinas HealthCare System, has been active on multiple fronts battling COVID-19. The nonprofit network of over 40 hospitals and over 900 care locations in North Carolina, South Carolina, and Georgia have also emerged as a leading player...

Trial Site Operation in San Antonio Reports Positive Momentum for Regeneron Monoclonal Antibody REGN-COV-2

TrialSite has reported that Lilly's monoclonal antibody (LY-CoV555) evidenced promise at a trial site location in southern Texas and that shortly thereafter recent interim analysis data from Lilly backed that observation. Now Regeneron’s monoclonal antibody cocktail...

Oxford RECOVERY Trial Investigates Regeneron’s REGN-COV2: Will it Reduce Mortality, Hospital Stay & Need for Ventilation?

The prominent global RECOVERY (Randomized Evaluation of COVid-19 thERapY) is one of the world’s largest randomized clinical trials of potential COVID-19 treatments. It was this study that discovered the benefit of dexamethasone in severe COVID-19 cases. The University...

Sioux Falls-based Avera Health Joins REGN-COV2 Clinical Trials Investigating Powerful Monoclonal Antibodies Targeting COVID-19

Regeneron has selected a Sioux Falls-based health care system called Avera Health as a Phase 2 and 3 trial site for the ongoing lab-produced monoclonal antibody combination, known as REGN-COV2, targeting COVID-19. Avera Health, a fully integrated health system...

East Coast Institute for Research Takes on REGN-COV2 Phase 3 Clinical Trial for those Exposed to Someone with COVID-19

East Coast Institute for Research, a clinical investigational site in Jacksonville, Florida, will commence a novel clinical trial next week testing Regeneron’s REGN-COV2, the monoclonal antibody designed to target SARS-COV-2. The study will be led by Dr. Rebecca...

Pin It on Pinterest